London, United Kingdom

Kenneth Powell


Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Kenneth Powell: Advancements in Pharmaceutical Composition

Introduction

Kenneth Powell is a notable inventor based in London, GB, recognized for his contribution to the field of pharmaceuticals. With a focus on developing innovative therapeutic solutions, Powell has made significant strides in addressing viral infections, particularly through his patented inventions.

Latest Patents

Powell holds one patent, which is a pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein. This composition includes a pharmaceutically acceptable carrier or diluent, an inhibitor of the RSV fusion protein, and a benzodiazepine derivative capable of inhibiting RSV replication. His invention has demonstrated high activity against Respiratory Syncytial Virus (RSV), showcasing its potential impact on treatment options within the pharmaceutical industry.

Career Highlights

Currently, Kenneth Powell is affiliated with Arrow Therapeutics Limited, a company dedicated to developing innovative antiviral therapies. His work within the organization is instrumental in advancing research and development focused on combating viral infections.

Collaborations

Throughout his career, Powell has collaborated with esteemed colleagues, including Richard Kelsey and Malcolm Clive Carter. Their combined expertise has facilitated the exploration of new avenues within pharmaceutical research, contributing to the progression of novel therapeutic approaches.

Conclusion

Kenneth Powell's work exemplifies the essence of innovation in the pharmaceutical sector. His patent for a composition targeting RSV highlights the importance of ongoing research and development in addressing significant medical challenges. As he continues to collaborate with fellow experts, Powell's contributions will likely lead to further breakthroughs in antiviral therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…